COVID-19 Associated Collapsing FSGS in an APOL1 Homozygous Transplant Recipient After Successful COVID Vaccination: A Case Report.

Abstract

Organ transplant recipients exhibit lower rates of immune response to coronavirus disease 2019 (COVID-19) vaccination. Even when they do mount a demonstrable antibody response, it is unclear what degree of protection is conferred against the myriad potential complications of COVID-19 infection. We present here a case of a kidney transplant recipient who was homozygous for APOL1 risk alleles on low-dose immunosuppression who developed an antibody response to COVID-19 vaccination and subsequently acquired COVID-19 infection. Although she experienced relatively minor effects in other organ systems, she developed severe collapsing focal segmental glomerulosclerosis that left her dependent on hemodialysis on hospital discharge. This suggests that COVID-19 vaccination may not provide protection from infection-associated focal segmental glomerulosclerosis in patients with APOL1 risk alleles.

• Authors: Shirui Chen, Jolanta Kowalewska, Thomas R McCune
• Journal: Transplantation proceedings (Transplant Proc) 2022 Jul-Aug Vol. 54 Issue 6 Pg. 1543-1546 ISSN: 1873-2623 [Electronic] United States
• PMID: 34924204 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2021 Elsevier Inc. All rights reserved.

Chemical References

• APOL1 protein, human
• Apolipoprotein L1
• COVID-19 Vaccines

Topics

• Apolipoprotein L1 (genetics)
• COVID-19 (prevention & control)
• COVID-19 Vaccines (adverse effects)
• Female
• Glomerulosclerosis, Focal Segmental (chemically induced)
• Humans
• Transplant Recipients
• Vaccination (adverse effects)